about
Systematic review of adherence rates by medication class in type 2 diabetes: a study protocolIdentification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study.Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study.The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cellsAudit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results.Diabetes screening after gestational diabetes in England: a quantitative retrospective cohort study.Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK.Glucose test provenance recording in UK primary care: was that fasted or random?Improving the measurement of longitudinal change in renal function: automated detection of changes in laboratory creatinine assay.A simple clinical coding strategy to improve recording of child maltreatment concerns: an audit study.A simple clinical coding strategy to improve recording of child maltreatment concerns: an audit studyPeripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus.Falls in the elderly were predicted opportunistically using a decision tree and systematically using a database-driven screening tool.Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results.A Class Comparison of Medication Persistence in People with Type 2 Diabetes: A Retrospective Observational Study.Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.A dynamic multi-compartmental model of DNA methylation with demonstrable predictive value in hematological malignancies.A systematic study comparing aspirate versus trephine for quantifying plasma cell infiltration in newly-diagnosed myeloma.Infection risk in elderly people with reduced glycaemic control.Basing approval of drugs for type 2 diabetes on real world outcomesWhat to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND studyDNMT3A mutations at R882 hotspot are only found in major clones of acute myeloid leukemiaDisparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysisRisk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
P50
Q28079475-9D3085D1-B7A8-4B22-A022-3C47F112E3F5Q30870783-6CA9EDA9-250D-4A41-BB50-A1BED8F2CC86Q33588053-4B6E8577-A821-4FB2-A244-088EBC03E763Q34990456-4D74886B-39E0-4E8A-989D-8EABF21995F6Q36972667-031B4632-5DA7-43F8-9EC0-6CC42834295FQ37186899-301B24D5-1F59-4249-ACEC-794F8673DD26Q37421091-4C0212B3-4727-4DE0-8935-76ED20F00359Q37516672-E42DD729-5235-4F8F-8D83-E8AC91FFB402Q40102041-EE450CA6-9AEB-4DE7-8FFB-740B14274C89Q40657694-28209814-DF31-4F12-8C83-E2BA657EF180Q40998123-409AE2C2-6279-46B0-B6B3-8BBDE76C6CE5Q42749347-B3D7D239-11F5-4F29-B1F4-AA216FA2E91BQ44536531-633CBCE7-6893-4AC3-8657-526BEA967D8AQ45806832-31A6945F-F5E7-4077-B040-F19C5E8F1CF7Q46273026-3D0D561A-9571-41D0-9BED-FAA3E7A7515AQ47557571-FA83C128-2CA9-4C64-94C5-8AD7CBA25951Q48308245-F597DEAD-A80C-4A6A-A702-BF1949C235BEQ51351456-EB4BAC48-23B8-415F-A478-D9B648444984Q53303274-922C56D8-2E27-499D-A41D-156E24111289Q54658384-465F4139-0F18-4BC6-A680-238E40FEB78CQ57249917-1AF71E0B-E0AE-4562-998E-7C83FC9CD782Q64117951-2B35091C-439E-4971-9392-BEB12DBD9EBFQ86907619-6ABFC176-EDD6-4F6D-AEE3-E6E1F22CBD49Q90561790-C7BDBD01-3312-4314-8ADE-A0291BD2F10FQ95654562-DF01793F-FE8D-477F-B9BC-AD5485446D3F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew McGovern
@ast
Andrew McGovern
@en
Andrew McGovern
@es
Andrew McGovern
@nl
Andrew McGovern
@sl
type
label
Andrew McGovern
@ast
Andrew McGovern
@en
Andrew McGovern
@es
Andrew McGovern
@nl
Andrew McGovern
@sl
altLabel
AP McGovern
@en
Andrew P McGovern
@en
prefLabel
Andrew McGovern
@ast
Andrew McGovern
@en
Andrew McGovern
@es
Andrew McGovern
@nl
Andrew McGovern
@sl
P106
P21
P31
P496
0000-0002-6833-9399
P569
2000-01-01T00:00:00Z